Trial reportPediatric nephrology (Berlin, Germany)2008
Mycophenolate mofetil versus cyclosporine for remission maintenance in nephrotic syndrome.
Trial report in Pediatric nephrology (Berlin, Germany), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 8 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.The Cochrane database of systematic reviews · 2024Pooled it
- Immunosuppressive agents for frequently relapsing/steroid-dependent nephrotic syndrome in children: a systematic review and network meta-analysis.Frontiers in immunology · 2024Pooled it
- Pediatric idiopathic steroid-sensitive nephrotic syndrome: diagnosis and therapy -short version of the updated German best practice guideline (S2e) - AWMF register no. 166-001, 6/2020.Pediatric nephrology (Berlin, Germany) · 2021Guideline
- Mycophenolate Mofetil in the Treatment of Steroid-Dependent or Frequently Relapsing Nephrotic Syndrome in Children: A Meta-Analysis.Frontiers in pediatrics · 2021Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2020Guideline
- Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.The Cochrane database of systematic reviews · 2020Pooled it
- Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy.Clinical and experimental nephrology · 2015Guideline
- Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO.Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2015Trial
- Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome.Journal of the American Society of Nephrology : JASN · 2013Trial
- Mycophenolate mofetil for steroid-dependent nephrotic syndrome: a phase II Bayesian trial.Pediatric nephrology (Berlin, Germany) · 2012Trial
- Mycophenolate mofetil therapy for children with steroid-resistant nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome.British journal of clinical pharmacology · 2010Trial
- Discontinuation of mycophenolate mofetil as maintenance therapy after rituximab treatment in childhood-onset complicated frequently relapsing or steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2026Observational
- Mycophenolate mofetil versus tacrolimus for maintenance of remission in children with frequently relapsing and steroid-dependent nephrotic syndrome: a pilot randomized controlled trial.Pediatric nephrology (Berlin, Germany) · 2026Article
- Steroid-sensitive nephrotic syndrome in children: Korean Society of Pediatric Nephrology clinical practice recommendations.Childhood kidney diseases · 2025Article
- Steroid-sensitive nephrotic syndrome in children: Korean Society of Pediatric Nephrology clinical practice recommendations.Kidney research and clinical practice · 2025Article
- A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy.Clinical and experimental nephrology · 2025Review
- Clinical applicability of 2023 International Pediatric Nephrology Association recommended limited therapeutic drug monitoring formulae to assess mycophenolic acid exposure.Pediatric nephrology (Berlin, Germany) · 2025Article
- Prolonged remission after cyclophosphamide or tacrolimus treatment in childhood nephrotic syndrome: a cohort study.Pediatric nephrology (Berlin, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We performed a multi-centre randomized controlled trial to compare the efficacy of mycophenolate mofetil (MMF) to that of cyclosporine A (CsA) in treating children with frequently relapsing nephrotic syndrome and biopsy-proven minimal change disease. Of the 31 randomized initially selected patients, seven were excluded. The remaining 24 children received either MMF 1200 mg/m(2) per day (n = 12) or CsA 4-5 mg/kg per day (n = 12) during a 12-month period. Of the 12 patients in the MMF group, two discontinued the study medication. Evaluation of the changes from the baseline glomerular filtration rate showed an overall significant difference in favour of MMF over the treatment period (p = 0.03). Seven of the 12 patients in the MMF group and 11 of the 12 patients in the CsA group remained in complete remission during the entire study period. Relapse rate in the MMF group was 0.83/year compared to 0.08/year in the CsA group (p = 0.08). None of the patients reported diarrhea. Pharmacokinetic profiles of mycophenolic acid were performed in seven patients. The patient with the lowest area under the curve had three relapses within 6 months. In children with frequently relapsing minimal change nephrotic syndrome, MMF has a favourable side effect profile compared to CsA; however, there is a tendency towards a higher relapse risk in patients treated with MMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.